Sol-Gel Technologies Prices Oversubscribed Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2026
0mins
Should l Buy SLGL?
Source: NASDAQ.COM
- Successful Offering: Sol-Gel Technologies announced the pricing of its oversubscribed public offering, reflecting strong investor interest in its dermatology pipeline, with proceeds aimed at working capital and supporting ongoing clinical development, particularly late-stage trials of its lead program.
- Clinical Progress: SGT-610 (Patidegib gel, 2%) is currently in Phase 3 trials aimed at preventing new basal cell carcinomas in Gorlin syndrome patients, with top-line results expected in Q4 2026, and if approved, it could become the first preventive treatment for this condition.
- Market Opportunity: The Phase 2 trial for SGT-610 targeting high-frequency basal cell carcinoma is planned to start between H2 2027 and H1 2028, focusing on patients who develop multiple BCCs over their lifetime, representing a significant market opportunity.
- Product Portfolio: The FDA-approved products TWYNEO and EPSOLAY provide a commercial foundation as the company advances its earlier-stage candidates, with TWYNEO combining two established agents and EPSOLAY treating inflammatory lesions of rosacea, supported by multiple commercial agreements across four continents.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLGL
Wall Street analysts forecast SLGL stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 68.540
Low
50.00
Averages
50.00
High
50.00
Current: 68.540
Low
50.00
Averages
50.00
High
50.00
About SLGL
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sol-Gel Technologies Prices Oversubscribed Public Offering
- Successful Offering: Sol-Gel Technologies announced the pricing of its oversubscribed public offering, reflecting strong investor interest in its dermatology pipeline, with proceeds aimed at working capital and supporting ongoing clinical development, particularly late-stage trials of its lead program.
- Clinical Progress: SGT-610 (Patidegib gel, 2%) is currently in Phase 3 trials aimed at preventing new basal cell carcinomas in Gorlin syndrome patients, with top-line results expected in Q4 2026, and if approved, it could become the first preventive treatment for this condition.
- Market Opportunity: The Phase 2 trial for SGT-610 targeting high-frequency basal cell carcinoma is planned to start between H2 2027 and H1 2028, focusing on patients who develop multiple BCCs over their lifetime, representing a significant market opportunity.
- Product Portfolio: The FDA-approved products TWYNEO and EPSOLAY provide a commercial foundation as the company advances its earlier-stage candidates, with TWYNEO combining two established agents and EPSOLAY treating inflammatory lesions of rosacea, supported by multiple commercial agreements across four continents.
See More
Sol-Gel Technologies Raises $33.1M in Oversubscribed Offering
- Offering Size: Sol-Gel Technologies successfully priced an oversubscribed public offering of approximately 459,000 shares at $72.00 each, raising about $33.1 million, indicating strong market demand despite a 9% drop in stock price during the same period.
- Use of Proceeds: The funds will be allocated to the continued development of SGT-610, including pre-commercialization activities and R&D, aimed at preventing new basal cell carcinomas in patients with Gorlin syndrome, thereby enhancing the company's competitive edge in skin cancer treatment.
- Market Reaction: Despite the successful fundraising, Sol-Gel's stock price fell to $66.20 during pre-market trading on Tuesday, reflecting investor concerns about the company's future performance, particularly its reliance on upcoming Q4 catalysts.
- Future Outlook: The offering is expected to close around March 25, 2026, and if SGT-610's development proceeds smoothly, it could present new growth opportunities for the company; however, market confidence in its success still needs to be validated through the upcoming earnings report.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
What’s Causing the Decline of Small Cap Sol-Gel Tech Stock Today?
Clinical Study Update: Sol-Gel Technologies announced that the Phase 1b study of SGT-210 for Darier disease did not show efficacy compared to the vehicle, leading to a decision not to advance further in this indication. The company plans to conduct small feasibility studies in other areas of unmet medical need.
Focus on Other Programs: The Executive Chairman, Mori Arkin, emphasized the company's commitment to completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparing for a potential Phase 3 program in high-frequency basal cell carcinoma, contingent on the success of the Gorlin trial.
Stock Performance Analysis: Sol-Gel Technologies (SLGL) is currently showing strong technical indicators, trading above key moving averages, with a bullish trend supported by positive momentum in the MACD and a neutral RSI.
Recent Stock Movement: SLGL stock experienced a decline of 6.81% to $39.26, while over the past year, it has gained 735.02%, indicating a strong upward trajectory but caution is advised as it approaches resistance levels.
See More
Sol-Gel Technologies' SGT-210 Fails to Show Efficacy in Darier Disease Trial
- Clinical Trial Outcome: Sol-Gel Technologies' Phase 1b study of SGT-210 for Darier disease failed to demonstrate efficacy over the vehicle control, leading to the decision not to advance the drug, indicating a significant shift in R&D strategy.
- Resource Reallocation: The company plans to pursue small, low-cost feasibility studies in other areas of unmet medical need, aiming to optimize resource allocation and mitigate R&D risks in light of recent trial results.
- Focus on Key Projects: Sol-Gel will continue to prioritize the Phase 3 trial of SGT-610 for Gorlin syndrome, which, if successful, could become the first treatment to prevent basal cell carcinoma in these patients, representing significant market potential.
- Market Challenges: The failure of SGT-210 places Sol-Gel under increased competitive pressure in the dermatology market, potentially affecting its future investment appeal and shareholder confidence.
See More
Sol-Gel Technologies Halts SGT-210 Development, Shifts Focus to Other Studies
- Clinical Trial Results: Sol-Gel's Phase 1b study of SGT-210 did not demonstrate efficacy over the vehicle control, leading to the decision to halt further development, marking a significant setback in treating Darier disease.
- Resource Reallocation: The company plans to conduct small, low-cost feasibility studies to explore SGT-210's application in other areas of unmet medical need, aiming to recover investment losses through new research directions.
- Focus on Key Projects: Sol-Gel continues to prioritize the Phase 3 trial of SGT-610, which has the potential to be the first treatment for preventing basal cell carcinoma in Gorlin syndrome patients, demonstrating the company's ongoing commitment to dermatological therapies.
- Market Challenges: With Gorlin syndrome affecting approximately 1 in 27,000 to 31,000 people in the U.S., despite significant market potential, Sol-Gel faces intense industry competition and resource constraints that may impact its future market performance.
See More
Sol-Gel Technologies Prices Oversubscribed Public Offering
- Successful Offering: Sol-Gel Technologies announced the pricing of its oversubscribed public offering, reflecting strong investor interest in its dermatology pipeline, with proceeds aimed at working capital and supporting ongoing clinical development, particularly late-stage trials of its lead program.
- Clinical Progress: SGT-610 (Patidegib gel, 2%) is currently in Phase 3 trials aimed at preventing new basal cell carcinomas in Gorlin syndrome patients, with top-line results expected in Q4 2026, and if approved, it could become the first preventive treatment for this condition.
- Market Opportunity: The Phase 2 trial for SGT-610 targeting high-frequency basal cell carcinoma is planned to start between H2 2027 and H1 2028, focusing on patients who develop multiple BCCs over their lifetime, representing a significant market opportunity.
- Product Portfolio: The FDA-approved products TWYNEO and EPSOLAY provide a commercial foundation as the company advances its earlier-stage candidates, with TWYNEO combining two established agents and EPSOLAY treating inflammatory lesions of rosacea, supported by multiple commercial agreements across four continents.
See More
Sol-Gel Technologies Raises $33.1M in Oversubscribed Offering
- Offering Size: Sol-Gel Technologies successfully priced an oversubscribed public offering of approximately 459,000 shares at $72.00 each, raising about $33.1 million, indicating strong market demand despite a 9% drop in stock price during the same period.
- Use of Proceeds: The funds will be allocated to the continued development of SGT-610, including pre-commercialization activities and R&D, aimed at preventing new basal cell carcinomas in patients with Gorlin syndrome, thereby enhancing the company's competitive edge in skin cancer treatment.
- Market Reaction: Despite the successful fundraising, Sol-Gel's stock price fell to $66.20 during pre-market trading on Tuesday, reflecting investor concerns about the company's future performance, particularly its reliance on upcoming Q4 catalysts.
- Future Outlook: The offering is expected to close around March 25, 2026, and if SGT-610's development proceeds smoothly, it could present new growth opportunities for the company; however, market confidence in its success still needs to be validated through the upcoming earnings report.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
What’s Causing the Decline of Small Cap Sol-Gel Tech Stock Today?
Clinical Study Update: Sol-Gel Technologies announced that the Phase 1b study of SGT-210 for Darier disease did not show efficacy compared to the vehicle, leading to a decision not to advance further in this indication. The company plans to conduct small feasibility studies in other areas of unmet medical need.
Focus on Other Programs: The Executive Chairman, Mori Arkin, emphasized the company's commitment to completing the Phase 3 program for SGT-610 in Gorlin syndrome and preparing for a potential Phase 3 program in high-frequency basal cell carcinoma, contingent on the success of the Gorlin trial.
Stock Performance Analysis: Sol-Gel Technologies (SLGL) is currently showing strong technical indicators, trading above key moving averages, with a bullish trend supported by positive momentum in the MACD and a neutral RSI.
Recent Stock Movement: SLGL stock experienced a decline of 6.81% to $39.26, while over the past year, it has gained 735.02%, indicating a strong upward trajectory but caution is advised as it approaches resistance levels.
See More
Sol-Gel Technologies' SGT-210 Fails to Show Efficacy in Darier Disease Trial
- Clinical Trial Outcome: Sol-Gel Technologies' Phase 1b study of SGT-210 for Darier disease failed to demonstrate efficacy over the vehicle control, leading to the decision not to advance the drug, indicating a significant shift in R&D strategy.
- Resource Reallocation: The company plans to pursue small, low-cost feasibility studies in other areas of unmet medical need, aiming to optimize resource allocation and mitigate R&D risks in light of recent trial results.
- Focus on Key Projects: Sol-Gel will continue to prioritize the Phase 3 trial of SGT-610 for Gorlin syndrome, which, if successful, could become the first treatment to prevent basal cell carcinoma in these patients, representing significant market potential.
- Market Challenges: The failure of SGT-210 places Sol-Gel under increased competitive pressure in the dermatology market, potentially affecting its future investment appeal and shareholder confidence.
See More
Sol-Gel Technologies Halts SGT-210 Development, Shifts Focus to Other Studies
- Clinical Trial Results: Sol-Gel's Phase 1b study of SGT-210 did not demonstrate efficacy over the vehicle control, leading to the decision to halt further development, marking a significant setback in treating Darier disease.
- Resource Reallocation: The company plans to conduct small, low-cost feasibility studies to explore SGT-210's application in other areas of unmet medical need, aiming to recover investment losses through new research directions.
- Focus on Key Projects: Sol-Gel continues to prioritize the Phase 3 trial of SGT-610, which has the potential to be the first treatment for preventing basal cell carcinoma in Gorlin syndrome patients, demonstrating the company's ongoing commitment to dermatological therapies.
- Market Challenges: With Gorlin syndrome affecting approximately 1 in 27,000 to 31,000 people in the U.S., despite significant market potential, Sol-Gel faces intense industry competition and resource constraints that may impact its future market performance.
See More
